A is trading at $139.39 (up 5.1%) in pre-market trading after delivering Q2 fiscal 2026 earnings and revenue above analyst expectations alongside an upward revision to full-year EPS guidance.
- The move extends a strong recent run for the stock, reinforcing bullish sentiment around its diagnostics and life-science tools business.
- The updated outlook follows a pattern of better-than-expected quarterly results and raised guidance that previously triggered double-digit gains for the company.